产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
首页 制药产品大全 药品制剂 Ginkgolide inje...

Ginkgolide injection

2026-02-27
成都市

产品详情

Ginkgolide injection
心脑血管及循环系统类制剂
Ginkgolide injection
北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

产品描述

Active ingredients: bilobalide, ginkgolide A, ginkgolide B and ginkgolide C.

Description: a colorless or pale-yellow clear liquid.

Dosage Form: liquid injection.
Indications: For mild to moderate cerebral infarction, symptoms are hemiplegia, deviated tongue, paralalia and paraesthesia, etc.
Strength: 2ml/ampoule, containing 10mg ginkgolide.

Storage: Keep airtight in a dark and cool place.

Packaging: ampoule, 5 ampoules/box (Can be customized based on customer's order.)

Shelf Life: 24months.
Dosage and Administration:
Administrated by intravenous infusion. The recommended dose is 5 bottles (10ml). Before use, add the powder into 250ml of 0.9% sodium chloride injection or 250ml of 5% glucose injection for dilution and administrated as a slow intravenous infusion. Give the dosage once a day; during the infusion, strictly control the rate ranging from 40 to 60 drops per minute. The course of treatment is 14 days.
Contradictions:
1. Patients with a history of hypersensitivity or adverse reaction to the product or any other finished ginkgo products.
2. Patients with a history of hypersensitivity to ethanol, glycerin, ethanol (alcohol) and glycerol.
3. Contradicted in pregnant and lactating women.
Pharmacology and toxicology:
The results of non-clinical pharmacodynamic study showed that the product can reduce the stroke score, the mortality rate and the cerebral infarction area in the rat  focal cerebral ischemia model using the suture method; can promote the recovery of  amplitude of EEG potential, can reduce cerebral ** content in the gerbil cerebral ischemia-reperfusion model; can reduce brain wet weight, brain index, cerebral ** content in the rat cerebral ischemia-reperfusion model using 4-vessel occlusion method, reduce the damage of hippocampal CA1 (increase the density of neuron in the region).

 

 

CDMO Service Undertaking

Dosage Form

Production Lines

Annual Capacity 

Injection

8

650,000,000

Oral Solid

3

700,000,000

API & Intermediates

3

8,000 Kg

TCM Extraction

2

5,000,000 Kg 

Baiyu provide CDMO service for:

FDFs & APIs
Primary & secondary packaging
Warehousing
Commercial scale, pilot scale, laboratory scale

You are warmly welcomed to contact us for business cooperation.

sales@baiyu.cn

Chengdu Baiyu Pharmaceutical Co., Ltd.

www.baiyujituan.com

四川宏明博思药业有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

四川宏明博思药业有限公司成立于2013年,专注于原料药和制剂的生产。现有员工400余人,主要生产高端剂型如注射剂、冻干粉针剂、片剂和胶囊剂。宏明博思的冻干粉针制剂生产线已获得EU GMP,并通过巴西ANVISA现场检查。目前四川宏明博思冻干粉针制剂的多个产品在巴西、智利、秘鲁、危地马拉、泰国、菲律宾、马来西亚、南非、澳大利亚等开展注册中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
业务类型:
成立日期:
年营业额:
主营产品类别: